$BIIB Wells Fargo analyst Jim Birchenough lowered the firm's price target on Biogen to $338 from $437 and keeps an Overweight rating on the shares. The analyst cites Friday's negative PCNS AdCom review of aducanumab as a treatment for early Alzheimer's disease. While the PCNS panel clearly rejected arguments in support of aducumab effectiveness, Birchenough believes that possibility of approval still exists given positive FDA bias, significant unmet need, absence of any credible alternative over the next 5-plus years and some precedent of FDA not following AdCom panel advice. Read more at: https://thefly.com/n.php?id=3192106 Все будет хорошо:)